EUCTR2015-002058-11-IT进行中（未招募）1 期
RIMMEL STUDY: Radiotherapy and ipilimumab in melanoma. Phase II clinical trial in patients with metastatic melanoma - RIMMEL STUDY
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Diagnosis of stage III-IV melanoma with indication to treatment with ipilimumab
- •- Two or more metastatic lesions measurable criteria mWHO immunocorrelati (24)
- •- Age> = 18
- •- Life expectancy >= 4 months
- •- ECOG 0-1
- •- Adequate bone marrow function (WBC> 3.0 x 10 ^ 3 / pL; N> 1.5 x 10 ^ 3 / pL; PLT> 100 x10 ^ 3 / pL; Hb> 10 g / dL)
- •- Adequate renal function (serum creatinine <= 1.5xUNL).
- •- Adequate hepatic function (Total bilirubin <= 1.5xUNL; AST-SGOT, SGPT ALT-<= 2.5xUNL; FAL and ¿GT <= 5xUNL)
- •- Written informed consent
- •- Geographical accessibility
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •- Untreated brain metastases or progression phase
- •- Impediments logistics of the patient to participate in the study, and to afferire with regularity at the center participant (as regards the treatment part and the subsequent part of follow-up).
- •- Presence of clinically significant cardiovascular disease. For example: Cerebrovascular accident (within 1 year), acute coronary syndrome (within 1 year), unstable angina, symptomatic heart failure (New York Heart Association - NYHA) grade II or higher, cardiac arrhythmia applicant drug therapy.
- •-There is no known contraindications for each of the drugs used in the study (known hypersensitivity to the active substance, to lactose or to any of the excipients, hereditary fructose intolerance, peripheral sensory neuropathy with functional impairment, chronic inflammatory bowel disease and / or bowel obstruction , diverticulitis, patients in a state of malnutrition, patients with serious infections)
- •- Diagnosis of other malignancy with disease-free interval <5yrs from enrollment, with the exception of the squamous cell or basal and squamous skin, and cancer of the cervix in situ, breast cancer or bladder cancer.
- •- Presence of autoimmune diseases (excluding vitiligo)
- •- Previous treatment with antibody anti-CTLA-4
- •- Administration of vaccines up to 1 month before or after administration of ipilimumab
- •- Concomitant use of immunosuppressive drugs or use of systemic corticosteroids
- •- Presence of malabsorption, weight loss, active, diarrhea or grade = 2 seconds to NCI Common Toxicity Criteria vs. 4.03.
- •- Presence of residual toxicity from prior treatments symptomatic grade = 1 second NCI Common Toxicity Criteria vs. 4.03.
- •- Women who are pregnant or lactating.
- •- Women of childbearing age with positive pregnancy test or who refuse the test run (not considered fertile women with a history of amenorrhea for at least 12 months).
- •- Men and women of childbearing potential and sexually active who refuse or are unable to use contraceptive methods. They are accepted as methods of birth control during the duration of the study complete abstention or the use of two methods of birth control proven to be effective, one barrier (eg. Condoms) and one chemical (eg. Pill)
研究者
相似试验
招募中
2 期
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancerRecurrent prostate cancerC61Malignant neoplasm of prostateDRKS00025948niversitätsklinikum Freiburg49
进行中（未招募）
1 期
Evaluation of radiotherapy in combination with pembrolizumab in patients with recurrent prostate cancer after radical prostatectomyRecurrent prostate cancer - Patients with biochemical recurrence (BCR) or persisting prostate-specifiv antigen (PSA) after radical prostatectomy (RP)EUCTR2021-001291-42-DEniversitätsklinikum Freiburg49
终止
1 期
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant MelanomaMalignant MelanomaNCT01557114Gustave Roussy, Cancer Campus, Grand Paris19
进行中（未招募）
1 期
Does adding double immunotherapy to the combination of chemotherapy and radiotherapy result in a better anti-tumor efficacy?locally advanced non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003454-83-NLAmsterdam UMC, VU University Medical Center29
已完成
2 期
Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLClung carcinoma1003866610029107lung cancerNL-OMON48462Vrije Universiteit Medisch Centrum29